Detail akcie Harrow Health Rg online

Business Summary: Harrow, Inc. is a provider of ophthalmic disease management solutions. It offers a portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. Its product candidates include MELT-210, MELT-300 and MELT-400. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Harrow Inc revenues increased 38% to $183.2M. Net loss decreased 52% to $11.8M. Revenues reflect Branded segment increase of 74% to $121.6M. Lower net loss reflects Stock-based Compensation in SGA decrease of 28% to $8.3M (expense), FV Adjustments of Financial Investments decrease from $3.2M (expense) to $0K. Basic Earnings per Share excluding Extraordinary Items increased from -$0.68 to -$0.33.